To determine if dose dependency occurs with 2 weight‐based single doses of omeprazole
in a phenotyping study as well as to quantitate 3‐month intraindividual variability of …

Omeprazole (brand name Prilosec) is a first-generation proton pump inhibitor (PPI) used to
treat gastroesophageal reflux disease (GERD), gastric ulcers, duodenal ulcers, upper …

Physiologically-based pharmacokinetic (PBPK) modeling is a well-recognized method for
quantitatively predicting the effect of intrinsic/extrinsic factors on drug exposure. However …

Physiologically‐based pharmacokinetic (PBPK) modeling is being increasingly used in drug
development to avoid unnecessary clinical drug–drug interaction (DDI) studies and inform …

Purpose: The objective of this study was to improve the predictive performance of
cytochrome P450 (CYP) 2C19 substrates in Japanese subjects using physiologically based …

We verified a physiologically‐based pharmacokinetic (PBPK) model to predict cytochrome
P450 3A4/5‐mediated drug‐drug interactions (DDIs). A midazolam (MDZ)–ketoconazole …

The success of applications of physiologically‐based pharmacokinetic (PBPK) modeling in
drug development and drug labeling has triggered regulatory agencies to demand rigorous …

Aims Previous studies demonstrated direct correlation between CYP2C19 genotype and
BMS‐823778 clearance in healthy volunteers. The objective of the present study was to …

The objectives of this multiple-dose study were to compare the performance of a new
formulation of omeprazole (40 mg) with that of an established formulation and to assess the …

Abstract Cytochrome P450 2C19 (CYP2C19) is the main (or partial) cause for large
differences in the pharmacokinetics of a number of clinically important drugs. On the basis of …